Back to Journals » Cancer Management and Research » Volume 10

Safety and efficacy of microwave ablation for breast cancer thoracic metastases

Authors Liu B, Wu ZJ, Mo H, He JL, Lin X, Guan J, Wei CY, Yuan ZC

Received 9 June 2018

Accepted for publication 2 October 2018

Published 14 November 2018 Volume 2018:10 Pages 5685—5689

DOI https://doi.org/10.2147/CMAR.S176743

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 2

Editor who approved publication: Dr Rituraj Purohit


Bin Liu,1,* Zhenjie Wu,1,* Hao Mo,1,* Juliang He,1 Xiang Lin,1 Jian Guan,1 Changyuan Wei,2,* Zhenchao Yuan1,*

1Department of Bone and Soft Tissue Neurosurgery, Affiliated Tumor Hospital of Guangxi Medical University, Nanning 530021, Guangxi, People’s Republic of China; 2Department of Breast Tumor Surgery, Affiliated Tumor Hospital of Guangxi Medical University, Nanning 530021, Guangxi, People’s Republic of China

*These authors contributed equally to this work

Background: The objective of the study was to assess the safety and efficacy of microwave ablation (MWA) for breast cancer thoracic metastasis.
Materials and methods: Twelve patients in our institution with a single lesion of breast cancer thoracic metastases received MWA and invasive spine surgery from August 2014 to November 2016. MWA was executed using the MWA system (2,450 MHz) at 40 W or 50 W with thermometers to control the ablation end points. The pathology of thoracic metastases was confirmed through intraoperative biopsy before ablation. The postoperative complications were recorded. The patients were followed up at 1, 3 and 6 months with contrast-enhanced computed tomography and magnetic resonance imaging to monitor for tumor recurrence.
Results: The average duration of follow-up for breast cancer thoracic metastases patients (mean age 52.7±8.4 years) was 10.2 months. The rate of postoperative main complications was 8.3% (1/12). The recurrence rate was 16.6% (2/12) as confirmed by persistent enhancement.
Conclusion: MWA may be used as the adjuvant treatment for thoracic metastases of breast cancer. Results showed that few significant complications and less local recurrence occurred during the follow-up stage. Future research should aim at discovering more about the time controls for microwave–tissue interaction and treatment parameters before widespread use.

Keywords: breast cancer, thoracic metastasis, microwave ablation, complication

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]